GlassScriptPhysician profile
Amin A Yehya
NPI 1376720946
$397,873.05
in general payments reported to CMS, 2019-2025
26 companies · $140K in 2025
The $140K reported for 2025 was more than what 99% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37K · 2020: $31K · 2021: $26K · 2022: $47K · 2023: $45K · 2024: $72K · 2025: $140K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $128K · Consulting Fee: $71K · Honoraria: $26K · Travel and Lodging: $21K · Food and Beverage: $11K · Education: $401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $127,626.00 |
| Consulting Fee | $70,726.75 |
| Honoraria | $25,600.00 |
| Travel and Lodging | $21,489.49 |
| Food and Beverage | $10,671.39 |
| Education | $401.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $97,122.82 | 2019-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $54,376.89 | 2024-2025 | |
| Scpharmaceuticals INC. | $53,786.20 | 2024-2025 | |
| Akcea Therapeutics, INC. | $51,976.88 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $32,207.48 | 2022-2025 | Farxiga, Lokelma |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26,665.46 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $21,633.91 | 2025 | Assure Wcd |
| Novo Nordisk INC | $17,051.68 | 2023-2024 | Ozempic |
| Cvrx, INC. | $14,741.02 | 2019-2025 | Barostim Neo System |
| Bridgebio Pharma, INC. | $10,598.34 | 2025 | Attruby |
| Nuwellis, INC. | $9,696.16 | 2019-2025 | Aquadex Smartflow Console |
| Abbott Laboratories | $4,666.80 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Perclose Prostyle |
| Medtronic Vascular, INC. | $2,027.94 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.07 | 2024 | Jardiance |
| Impulse Dynamics (USA) INC. | $231.26 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endotronix, INC. | $225.48 | 2022 | |
| Alnylam Pharmaceuticals INC. | $179.20 | 2023 | Amvuttra |
| Vifor Pharma, INC. | $126.62 | 2023 | Veltassa |
| Medtronic, INC. | $120.03 | 2021 | |
| Lilly USA, LLC | $94.82 | 2025 | Zepbound |
| Abiomed | $40.60 | 2023 | Impella |
| Cardiva Medical, INC. | $30.22 | 2022 | |
| Phadia US INC. | $20.13 | 2022 | |
| Pfizer INC. | $15.04 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amin Yehya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.